Welcome from the ADNI Principal Investigator
Alzheimer’s disease (AD) affects almost 50% of those over the age of 85 and is the sixth leading cause of death in the US. Since 2005, the longitudinal Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been validating the use of biomarkers including blood tests, tests of cerebrospinal fluid, and MRI/ PET imaging for Alzheimer’s disease (AD) clinical trials and diagnosis.
Now in its third phase (ADNI, ADNI GO and ADNI 2), ADNI 2 is studying the rate of change of cognition, function, brain structure, and biomarkers in 150 elderly controls, 450 subjects with mild cognitive impairment, 150 with mild to moderate AD and a new group of 100 people with significant, yet subtle, memory complaints, referred to as the significant memory concern cohort.
Is there a common thread among ADNI participants? You bet. ADNI volunteers are the heart of study and the most prevalent characteristic among them may be altruism. Our participants make a multiyear commitment to a study that is providing the path toward treatment and prevention of AD while not offering any potential intervention. ADNI is currently enrolling participants who have been diagnosed with mild-to-moderate AD and also seeking participants with subtle, yet distinct, memory concerns. If you are interested in volunteering for ADNI, contact information for all North American ADNI sites can be found here.
ADNI also maintains an unprecedented data access policy intended to encourage new investigation and to increase the pace of discovery in the race to prevent, treat, and one day cure AD. All data is made available without embargo. Armed with better knowledge of the first indications of AD from ADNI and other studies, researchers are beginning to test potential therapies at the earliest stages feasible when there may the greatest promise for slowing down progression of this devastating disease.
This web site – adni-info.org – is informational and is intended to provide an introduction of ADNI study basics. Scientists and researchers seeking access to ADNI data should visit UCLA’s Laboratory of Neuroimaging ADNI database (ADNI LONI). Later this year, the ADNI LONI database will be significantly enriched with the addition of whole genome sequences (WGS) for 800 ADNI participants.
We welcome any suggestions or comments you may have regarding content on this site. Please direct any content related emails to
Michael W. Weiner MD
Principal Investigator, Alzheimer’s Disease Neuroimaging Initiative
Director, Center for Imaging of Neurodegenerative Disease
San Francisco VA Medical Center
University of California, San Francisco, U.S.A